Charles River Laboratories International, Inc. (CRL) · Sep 24, 2026 · Guidance

Charles River sets 2030 growth targets, but near-term guidance is only reaffirmed

Guidance reaffirmed — 2026 EPS remains $11.15–$11.45; company now expects the upper end

Charles River outlines a margin-and-growth reset through 2030, backed by $300M in savings, while 2026 guidance merely stays at the range’s upper end.

Charles River is trying to move from a post-downturn efficiency program back toward growth: second-quarter organic revenue was essentially flat, but DSA demand improved and operating margin recovered sequentially.

The filing gives that recovery a longer runway. Management introduced the “Pathway to Purpose” strategy, built around modernization, a stronger scientific portfolio, and a more integrated client experience. The direction was not a surprise—the company had already signaled that its 2026 Investor Day would update the strategy and long-term targets—but the specific 2030 framework is new. Charles River says the strategy is intended to “modernize the Company, strengthen its scientific portfolio, and drive profitable growth to enhance long-term shareholder value creation.” 〔0〕

Metric2026 guidance2030 target
Organic revenue growthUpper end of 0%–1%5%–7% CAGR, 2027–2030
Non-GAAP operating margin21.0%–21.3%Approximately 24%
Non-GAAP EPSUpper end of $11.15–$11.45Low-double-digit CAGR
Create the Future savings—More than $300 million, 2027–2030
Bioanalysis revenue—Approximately $450 million in 2030

The most tangible lever is cost, not immediate acceleration. The company expects more than $300 million of cumulative savings from 2027 through 2030 through simplification, automation, and digital tools. That is meaningful because Charles River is still emerging from a period of weak demand and restructuring, but the target is partly self-help: the filing does not provide a detailed bridge showing how much of the projected margin expansion comes from revenue growth versus savings. The company says, “Charles River expects to generate over $300million in cumulative savings from 2027 through 2030.”

The growth thesis is concentrated in scientific services that are still being rebuilt. Bioanalysis, in-vitro testing, complex modalities, and AI-assisted drug discovery are the priority areas; bioanalysis is targeted to reach roughly $450 million of revenue by 2030 at a high-single-digit organic CAGR. That gives the recovery a more specific commercial focus than a generic “return to growth” message, although the target depends on improving biopharma R&D demand and execution in businesses that have only recently begun stabilizing.

Near-term expectations improve modestly, but this is not a fresh guidance raise. Charles River kept its 2026 ranges intact and said revenue and non-GAAP EPS should land at their upper ends. That is incrementally better than a midpoint outcome, and published expectations were around $11.1 of adjusted EPS, but the range itself had already been raised on August 5, 2026. The filing explicitly says, “The Company now expects revenue and non-GAAP earnings per share to be at the upper ends of their respective guidance ranges.” 〔1〕

Bottom line: This is a credible strategic reset with a useful margin-and-growth roadmap, but the immediate financial message is only an upper-end reaffirmation. The event advances the recovery story, yet execution—not the headline targets—remains the main change still to prove.

What to watch next

Q3 results and updated DSA demand trends

Original filing on SEC EDGAR

More Charles River Laboratories International, Inc. news

Charles River sets 2030 growth targets, but near-term guidance is only reaffirmed | CRL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.